BlissBio Inc. saw its application for a Hong Kong initial public offering lapse on December 29, six months after it was first submitted on June 29. Goldman Sachs, Huatai International, and CCB International were the joint sponsors for the application.

According to the prospectus, BlissBio is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) to address significant unmet needs in current oncology treatments.

The company's core product, BB-1701, is a human epidermal growth factor receptor 2 (HER2)-targeted ADC candidate utilizing eribulin, primarily intended for breast cancer (BC), non-small cell lung cancer (NSCLC), and potentially other HER2-expressing cancers.